Volume | 600,639 |
|
|||||
News | - | ||||||
Day High | 2.30 | Low High |
|||||
Day Low | 2.02 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
NRX Pharmaceuticals Inc | NRXP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.06 | 2.02 | 2.30 | 2.18 | 2.58 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
3,108 | 600,639 | US$ 2.13 | US$ 1,277,628 | - | 2.02 - 12.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:42:20 | 50 | US$ 2.18 | USD |
NRX Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
182.11M | 83.92M | - | 0 | -30.16M | -0.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NRX Pharmaceuticals News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRXP Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.13 | 3.83 | 2.02 | 2.99 | 354,391 | -0.95 | -30.35% |
1 Month | 4.65 | 6.00 | 2.02 | 4.04 | 310,602 | -2.47 | -53.12% |
3 Months | 3.933 | 7.333 | 2.02 | 5.09 | 1,514,317 | -1.75 | -44.57% |
6 Months | 3.115 | 7.333 | 2.02 | 4.70 | 1,150,941 | -0.935 | -30.02% |
1 Year | 5.70 | 12.00 | 2.02 | 4.19 | 1,025,505 | -3.52 | -61.75% |
3 Years | 230.10 | 262.40 | 2.02 | 69.25 | 1,600,463 | -227.92 | -99.05% |
5 Years | 230.10 | 262.40 | 2.02 | 69.25 | 1,600,463 | -227.92 | -99.05% |
NRX Pharmaceuticals Description
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. |